McMahon Pamela M, Kong Chung Yin, Johnson Bruce E, Weinstein Milton C, Weeks Jane C, Kuntz Karen M, Shepard Jo-Anne O, Swensen Stephen J, Gazelle G Scott
Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA.
Radiology. 2008 Jul;248(1):278-87. doi: 10.1148/radiol.2481071446. Epub 2008 May 5.
To use individual-level data provided from the single-arm study of helical computed tomographic (CT) screening at the Mayo Clinic (Rochester, Minn) to estimate the long-term effectiveness of screening in Mayo study participants and to compare estimates from an existing lung cancer simulation model with estimates from a different modeling approach that used the same data.
The study was approved by institutional review boards and was HIPAA compliant. Deidentified individual-level data from participants (1520 current or former smokers aged 50-85 years) in the Mayo Clinic helical CT screening study were used to populate the Lung Cancer Policy Model, a comprehensive microsimulation model of lung cancer development, screening findings, treatment results, and long-term outcomes. The model predicted diagnosed cases of lung cancer and deaths per simulated study arm (five annual screening examinations vs no screening). Main outcome measures were predicted changes in lung cancer-specific and all-cause mortality as functions of follow-up time after simulated enrollment and randomization.
At 6-year follow-up, the screening arm had an estimated 37% relative increase in lung cancer detection, compared with the control arm. At 15-year follow-up, five annual screening examinations yielded a 9% relative increase in lung cancer detection. The relative reduction in cumulative lung cancer-specific mortality from five annual screening examinations was 28% at 6-year follow-up (15% at 15 years). The relative reduction in cumulative all-cause mortality from five annual screening examinations was 4% at 6-year follow-up (2% at 15 years).
Screening may reduce lung cancer-specific mortality but may offer a smaller reduction in overall mortality because of increased competing mortality risks associated with smoking.
利用梅奥诊所(明尼苏达州罗切斯特)螺旋计算机断层扫描(CT)筛查单臂研究提供的个体水平数据,评估梅奥研究参与者筛查的长期效果,并将现有肺癌模拟模型的估计值与使用相同数据的不同建模方法的估计值进行比较。
本研究经机构审查委员会批准,并符合健康保险流通与责任法案(HIPAA)。来自梅奥诊所螺旋CT筛查研究参与者(1520名年龄在50 - 85岁的现吸烟者或既往吸烟者)的去识别化个体水平数据被用于填充肺癌政策模型,这是一个关于肺癌发展、筛查结果、治疗效果和长期结局的综合微观模拟模型。该模型预测了每个模拟研究组(五年每年进行一次筛查与不进行筛查)的肺癌诊断病例数和死亡数。主要结局指标是预测肺癌特异性死亡率和全因死亡率随模拟入组和随机分组后随访时间的变化。
在6年随访时,与对照组相比,筛查组肺癌检测估计相对增加37%。在15年随访时,五年每年进行一次筛查使肺癌检测相对增加9%。五年每年进行一次筛查导致的累积肺癌特异性死亡率在6年随访时相对降低28%(15年时为15%)。五年每年进行一次筛查导致的累积全因死亡率在6年随访时相对降低4%(15年时为2%)。
筛查可能降低肺癌特异性死亡率,但由于与吸烟相关的竞争性死亡风险增加,对总体死亡率的降低幅度可能较小。